2.35
price up icon0.86%   0.02
after-market After Hours: 2.66 0.31 +13.19%
loading
Gt Biopharma Inc stock is traded at $2.35, with a volume of 17,138. It is up +0.86% in the last 24 hours and up +7.80% over the past month. GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
See More
Previous Close:
$2.33
Open:
$2.2019
24h Volume:
17,138
Relative Volume:
0.03
Market Cap:
$5.96M
Revenue:
-
Net Income/Loss:
$-9.64M
P/E Ratio:
-0.3394
EPS:
-6.9236
Net Cash Flow:
$-10.11M
1W Performance:
-2.08%
1M Performance:
+7.80%
6M Performance:
+16.34%
1Y Performance:
-46.13%
1-Day Range:
Value
$2.2019
$2.39
1-Week Range:
Value
$2.1006
$2.46
52-Week Range:
Value
$1.72
$10.66

Gt Biopharma Inc Stock (GTBP) Company Profile

Name
Name
Gt Biopharma Inc
Name
Phone
(800) 304-9888
Name
Address
315 MONTGOMERY STREET, SAN FRANCISCO
Name
Employee
1
Name
Twitter
Name
Next Earnings Date
2024-12-08
Name
Latest SEC Filings
Name
GTBP's Discussions on Twitter

Compare GTBP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
0.2846 0 0 0 0 0.00
 icon
GOODO
Gladstone Commercial Corporation
19.95 372.90M 0 0 0 0.00
 icon
PSNYW
Polestar Automotive Holding Uk
0.16 337.66M 2.07B -1.42B -1.37B -0.6765
 icon
MOBBW
Mobilicom Limited Warrants
0.265 278.60M 0 0 0 0.00
 icon
SHMD
Schmid Group N V
3.25 139.95M 0 0 0 0.00
 icon
JUNE
Dhandho Junoon Etf
10.50 137.23M 0 0 0 0.00

Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-02-24 Initiated ROTH MKM Buy
May-24-21 Initiated H.C. Wainwright Buy
Apr-13-21 Initiated B. Riley Securities Buy
Mar-17-21 Initiated ROTH Capital Buy

Gt Biopharma Inc Stock (GTBP) Latest News

pulisher
05:16 AM

GT Biopharma Issues Warrant to Cytovance for Services Rendered - Investing.com

05:16 AM
pulisher
Apr 01, 2025

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 31, 2025
pulisher
Mar 28, 2025

Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily

Mar 28, 2025
pulisher
Mar 24, 2025

North American Morning Briefing : Stock Futures -2- - MarketScreener

Mar 24, 2025
pulisher
Mar 18, 2025

GT Biopharma (GTBP) Projected to Post Quarterly Earnings on Tuesday - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

Nanobodies Market Detailed In New Research Report 2025 | Sanofi, - openPR

Mar 17, 2025
pulisher
Mar 13, 2025

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Mar 13, 2025
pulisher
Mar 10, 2025

The Goodyear Tire & Rubber Company (GT): A Bull Case Theory - Yahoo Finance

Mar 10, 2025
pulisher
Mar 04, 2025

GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit - GlobeNewswire

Mar 04, 2025
pulisher
Mar 04, 2025

Can GT Biopharma's TriKE® Technology Transform Blood Cancer Treatment? Phase 1 Trial Updates Coming in 2025 - StockTitan

Mar 04, 2025
pulisher
Mar 03, 2025

GT Biopharma Launches Shareholder Communications Initiative - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 01, 2025

Roth Capital Has Weak Forecast for GT Biopharma Q1 Earnings - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

Analysts Issue Forecasts for GT Biopharma FY2029 Earnings - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

GT Biopharma Announces $7.1 Million Convertible Debt Financing - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak - Asianet Newsable

Feb 27, 2025
pulisher
Feb 25, 2025

GT Biopharma Announces Exercise of Warrants - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

"Signal Advance, Inc. (OTC: SIGL) Achieves Technology - openPR

Feb 25, 2025
pulisher
Feb 25, 2025

GT Biopharma announces warrant exercise, plans new offering - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

GT Biopharma announces warrant exercise, plans new offering By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

GTBPGt Biopharma Inc Latest Stock News & Market Updates - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Stock market today: Wah Fu Education Group +219.55%, Jet.AI +46.26% among top gainers in early trading - Business Upturn

Feb 25, 2025
pulisher
Feb 25, 2025

Artificial Intelligence (AI) News Live Feed - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

GT Biopharma withdraws SEC registration statement - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

GT Biopharma Pulls Back S-1 Filing: What Does This Mean for Their Financing Strategy? - StockTitan

Feb 25, 2025
pulisher
Feb 21, 2025

GT Biopharma, Inc. SEC 10-K Report - TradingView

Feb 21, 2025
pulisher
Feb 19, 2025

This New Nasdaq Biotech Could Revolutionize Emergency Cardiac CareHere's Why - StockTitan

Feb 19, 2025
pulisher
Feb 19, 2025

Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Expands By 5.1% - Defense World

Feb 19, 2025
pulisher
Feb 15, 2025

Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven - Yahoo Finance

Feb 15, 2025
pulisher
Feb 06, 2025

GT Biopharma Announces Recently Presented Data on Our Next Generation TriKE (OXS-C3550) at The Ash Meeting in Atlanta, GA - ACCESS Newswire

Feb 06, 2025
pulisher
Feb 05, 2025

Nanobodies Market Analysis: Growth Drivers in Targeted - openPR

Feb 05, 2025
pulisher
Feb 04, 2025

Pre-market Movers In Healthcare Sector: HUGE, ONTX, SVRA, CELC, CHFS... - RTTNews

Feb 04, 2025
pulisher
Jan 29, 2025

StockNews.com Initiates Coverage on Beasley Broadcast Group (NASDAQ:BBGI) - Defense World

Jan 29, 2025
pulisher
Jan 29, 2025

StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS) - Defense World

Jan 29, 2025
pulisher
Jan 29, 2025

Barnes Group (NYSE:B) Now Covered by StockNews.com - Defense World

Jan 29, 2025
pulisher
Jan 29, 2025

Apollo Commercial Real Estate Finance (NYSE:ARI) Stock Rating Lowered by StockNews.com - Defense World

Jan 29, 2025
pulisher
Jan 29, 2025

KULR Technology Group Announces Strategic Partnership with EDOM Technology - Defense World

Jan 29, 2025
pulisher
Jan 29, 2025

StockNews.com Begins Coverage on Power REIT (NYSE:PW) - Defense World

Jan 29, 2025
pulisher
Jan 29, 2025

Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com - Defense World

Jan 29, 2025
pulisher
Jan 29, 2025

Embrace Change Acquisition Corp. Enters Definitive Merger Agreement with Tianji for Public ListingSAN DIEGO, CA – January 27, 2025 – Embrace Change Acquisition Corp. (NASDAQ: EMCGU), a special purpose acquisition company, and Tianji Tire Global - Defense World

Jan 29, 2025
pulisher
Jan 29, 2025

Goldman Sachs Announces Adoption of Tax Benefit Preservation Plan - Defense World

Jan 29, 2025
pulisher
Jan 29, 2025

First Financial Bancorp Reports Solid Financial Performance in Fourth Quarter 2024 - Defense World

Jan 29, 2025
pulisher
Jan 29, 2025

Seaport Res Ptn Forecasts Weaker Earnings for Sands China - Defense World

Jan 29, 2025
pulisher
Jan 29, 2025

Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing - Defense World

Jan 29, 2025
pulisher
Jan 29, 2025

Cormark Weighs in on Real Matters’ FY2025 Earnings (TSE:REA) - Defense World

Jan 29, 2025
pulisher
Jan 29, 2025

AmpliTech Group, Inc. (NASDAQ:AMPG) Short Interest Down 60.9% in January - Defense World

Jan 29, 2025
pulisher
Jan 28, 2025

GT Biopharma Announces First Patient Dosed in Phase 1 Trial - GlobeNewswire

Jan 28, 2025
pulisher
Jan 27, 2025

GT Biopharma Announces Expanded TriKE(TM) Partnership With Cytovance Biologics - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 27, 2025

GT Biopharma, Inc. Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies - Marketscreener.com

Jan 27, 2025

Gt Biopharma Inc Stock (GTBP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Cap:     |  Volume (24h):